Purpose: Researchers are often interested in estimating treatment effects in subgroups controlling for confounding based on a propensity score (PS) estimated in the overall study population.
The active comparator, new user study design limited baseline covariate differences between sulfonylurea (SU) and metformin (MET) monotherapy initiators with type 2 diabetes mellitus (T2DM) before propensity score (PS) implementation. We found little indication for differential channeling between SU and MET in patients without cardiovascular disease (CVD) and with CVD. Balance of covariates across treatments was achieved with both overall and subgroup-specific PSs using matching and stratification in 3 different cohorts.
In comparative effectiveness research, covariate selection is critical in deriving PSs to control for confounding. [1] [2] [3] [4] [5] However, the effect of covariates on treatment may vary by subgroup. The impact of using a PS estimated in the overall cohort for prespecified subgroup analyses is not well understood. There may be efficiency and validity gains in estimating separate PSs for different subgroups but subgroup-specific PS derivation within multiple subgroups may not be practical, and correct specification of PS with multiple subgroups may be difficult, resulting in greater imbalances.
A recent study assessed whether using an overall cohort PS in subgroup analyses was feasible, finding that a cohort PS resulted in similar effect estimates as a subgroup-specific PS when the overall cohort PS is correctly specified, especially in larger subgroups. 6 That study focused on simulations and a specific example of antipsychotics and short-term mortality in 2 cohorts, however, and NSAIDS and severe gastrointestinal complications in 1 cohort.
In patients with T2DM, there is mixed evidence about the risk of myocardial infarction (MI) associated with SU relative to MET. [7] [8] [9] An important potential confounder for such analyses is history of CVD. 10 In this study, we extended the empirical work of Rassen et al 6 to cardiovascular events in T2DM using the design of the mini-Sentinel protocol. 10 We used 3 different administrative databases to assess the association of initiating SU versus MET monotherapy (new users) on nonfatal MI after conditioning (eg, matching or stratifying) on PSs derived within an overall cohort compared with conditioning on CVD subgroup-specific PSs with different approaches.
METHODS
We studied younger (aged below 65 y) patients from a large, US-based administrative claims database of a commercially insured population and their dependents (Clinformatics DataMart, OptumInsight previously known as i3 InVision Data Mart, Ingenix Inc.). This database is used extensively for pharmacoepidemiological research and contains > 45 million unique members spanning almost 10 years, of which > 29 million patients were continuously enrolled for at least 12 months.
We also studied older adults from Humana with Medicare Advantage Prescription Drug plans (Humana MA), who had both pharmacy and medical claims, and prescription drug plan claims. In 2010, Humana had over 3.2 million Medicare members including 2 million Medicare Advantage members, and there has typically been little plan turnover. 11 Finally, older adults from an approximate 20% random sample of Medicare beneficiaries 65 years or older enrolled in the stand-alone prescription drug plan and fee-for-service (FFS) components of Medicare claims data (Medicare FFS) from January 1, 2007 to December 31, 2009 were analyzed for this study. 12, 13 Within the commercially insured younger cohort, we identified adult patients aged 25-64 years with T2DM who were initiating monotherapy with SU or MET. In Humana MA and Medicare FFS claims, we identified new users of the same therapies who were 65 years old and above. T2DM was identified as those with at least one of the following: (a) at least 1 inpatient admission for which the principal diagnosis was recorded as diabetes; (b) at least 1 inpatient admission for which any diagnosis was recorded as diabetes coupled with another criterion [oral antihyperglycemic agent (OHA) prescription, inpatient or outpatient type 2 diabetes diagnoses, or laboratory result]; (c) at least 2 outpatient facility or physician office visit claims for which a diagnosis was recorded as diabetes; (d) at least 1 inpatient or outpatient claim of diabetes AND at least 1 prescription of OHA medication; or (e) at least 1 laboratory result of blood glucose >200 mg/ dL OR HbA 1C > 6.5%. 14, 15 Data were extracted for patients with T2DM with claims between January 1, 2003 and December 31, 2010 for the commercially insured (6 mo lookback period to July 1, 2002), January 1, 2008-July 31, 2011 for Humana MA (6 mo look-back period to July 1, 2007) , and from July 1, 2007 -December 31, 2009 in the Medicare FFS (6 mo look-back period to January 1, 2007) .
Patients were excluded if they met any of the following: (a) type 1 diabetes (identified by the 5th digit number of ICD-9 code), juvenile diabetes, malnutrition-associated diabetes, drug-induced diabetes, or gestational diabetes at any time in the database without subsequent type 2 diabetes code, or ketoacidosis; (b) 25 years or younger at first notation of a diabetes code; (c) diabetes ICD-9 code associated with a blood draw within 15 days with corresponding laboratory data indicating the glucose and HbA 1C results did not meet criteria for diabetes, and no prior or subsequent diabetes codes or OHA use; (d) any OHA prescription within 7 months before index date (first prescription of SU or MET during the study window); and (e) not having both medical and pharmacy benefits. SU and MET were identified using NDC codes recorded as part of paid prescription claims; hence, it is assured that the physician prescribed and the pharmacy filled the prescription.
Eligibility in terms of initiation of monotherapy required at least 2 consecutive prescriptions of MET or SU within 120 days. This improves the likelihood that the patient actually took the product given it was refilled. No patients meeting this criterion were excluded. Follow-up began at the second qualifying prescription and continued until the patient experienced an MI or was censored at the earliest occurrence of: (1) end of patient's enrollment or death, or (2) end of the study window. Patients who transitioned to Medicare during follow-up in the younger cohort were censored at transition. In the primary analysis, patients were not censored if they switched, discontinued, or augmented treatment with one of the drugs being compared. However, similar results were found in a secondary "as treated" analysis where patients were censored when they discontinued drug, switched, or augmented with SU or MET. Stopping was defined as having no additional prescription within the days supply plus a grace period of 30 days after the previous prescription.
The primary outcome of nonfatal acute myocardial infarction (AMI) was defined as a diagnosis based on hospital discharge ICD-9 code: 410.x0 or 410.x1 in the first or second position, or DRG codes 121, 122, 123. 10 No length of stay criterion was applied. Other cardiovascular outcomes typically included in composite endpoints of cardiovascular outcomes trials are typically not available in databases (fatal MI, other cardiovascular death), and revascularizations, unless urgent (distinction not available in database), are typically considered a "soft" outcome subject to substantial geographic variability and physician subjectivity. Hence, these outcomes were not studied.
The primary subgroup was defined as history of CVD in the prior 6 months. History of CVD included any CVD, that is, MI, CABG, PTCA, unstable angina, and peripheral arterial disease. 10 In addition, we included the following as prevalent CVD: lower extremity revascularization (38.18), endarterectomy (39.25, 39.29), lower extremity bypass (84.10-84.17), and procedure codes for carotid revascularization (38.11, 38.12), endarterectomy (00.61, 00.63), and carotid bypass (39.28).
Baseline comorbidities were determined by ICD-9 codes in the 6-month period before the index date, and included complications of diabetes, CVD, liver disease, lung disease, infection, cancer, and other diseases. Confounders and risk factors for nonfatal MI included in the PS models were selected using prior clinical and epidemiologic knowledge based on published literature (a priori), and consisted of age, sex and diagnoses (coded at the 3-digit level), procedures, and drugs (coded based on generic drug name) that had a prevalence of > 2% and < 98% in the 6-month baseline period to allow evaluation of which individually had the greatest imbalance. Also included in the traditional Medicare analyses were nursing home residence, number of hospitalizations, emergency department visits, number of outpatient physician visits, and number of distinct prescription drugs dispensed. Interactions were not accounted for in derivations of PS, as the main effects PS model balanced the groups fairly well. In the base-case scenario, we only included variables available in all 3 databases. In Medicare analyses, sensitivity analyses including variables unique to that database showed similar results.
Within each database population, we estimated 3 separate PSs for predicting treatment initiation with SU versus MET: an overall PS (including prior CVD as a covariate) and 2 separate PSs for the prior CVD subgroups. We implemented these PSs within each subgroup of CVD using a greedy algorithm for 1:1 matching 16 and equally sized PS deciles (quintiles for Medicare FFS) stratification after restricting to an overlapping PS range. Because the true effect (necessary to compare bias) is unknown in these empirical datasets, we primarily compared the balance within CVD subgroups based on the overall versus subgroup-specific PS. We also compared overall versus subgroup-specific PSs with respect to the point estimate of the hazard ratio (HR) and 95% confidence interval width for treatment with SU versus MET. The average standardized absolute mean difference (ASAMD) was used to assess balance within CVD subgroups, [17] [18] [19] with lower ASAMD indicating better balance. For the matched analyses, the ASAMD was calculated as the absolute value of the difference in means (percentages) divided by a pooled SD for each covariate, averaged across covariates. For the stratified analyses, we first calculated the ASAMD for each covariate within each PS stratum and then combined differences within covariate across strata, finally averaging over all covariates. We used Kaplan-Meier plots to assess the proportional hazards assumption and fit Cox proportional hazards models for time to event (acute non-fatal MI) over the entire follow-up if appropriate (PH assumption met).
RESULTS

Younger Cohort
Baseline characteristics of the younger cohort were generally comparable for MET and SU monotherapy new users, with the most pronounced differences at baseline before matching observed in sex, age, cardiovascular and renal diseases, nonskin cancers, and retinopathy (Table 1) . There was minimal nonoverlap between PSs overall ( Fig. 1 ), reflecting minimal imbalance in this younger cohort (crude ASAMD in subgroups without CVD history: 0.073, and with prior CVD: 0.099). CVD history was related to SU versus MET treatment in the PS model [1.49 (1.45, 1.53)]. With matches achieved for over 98% of the SU patients, baseline covariates were fairly well balanced with overall PS for the full cohort and within the subgroup without CVD history (ASAMD: 0.01 for both) as well as when the subgroupspecific PS was used (ASAMD: 0.01 for subgroup without CVD history) (Fig. 2) . Within the prior CVD subgroup where 92% of SU patients were matched, balance was only slightly better using the subgroup-specific PS (ASAMD: 0.01) than using the overall PS (ASAMD: 0.02).
With PS stratification, balance was achieved with both overall PS (ASAMD: 0.04) and subgroup-specific PS (ASAMD: 0.02) within the subgroup without CVD history, and in the subgroup with CVD history (ASAMD: 0.02 for both overall and subgroup-specific PS). ASAMD estimates were consistently lower for 1:1 matching than for stratification.
The crude HRs for nonfatal MI in the younger cohort with SU versus MET were 1.08 (1.05, 1.11) overall, 1.08 (1.04, 1.11) within the subgroup with no prior CVD history, and 1.05 (0.99, 1.13) for those with prior CVD (Fig. 3) . HR estimates were highly consistent (HR range, 1.1-1.15) between overall and subgroup-specific PS for 1:1 matching, differing by <1% in those without prior CVD, and only 3.5% in those with prior CVD. PS stratification showed similar patterns.
Older Medicare Cohorts
Baseline characteristics of the older cohorts were less similar than for the younger cohort, with the most pronounced differences before matching observed in age, sex, heart disease (prior MI, peripheral vascular disease, pacemakers, congestive heart failure), renal disease, bone fractures, and diabetes complications, likely due to the higher proportion of older age (above 80 y) in SU users (overall ASAMD: 00.35 in Humana MA, 0.11 in Medicare FFS). CVD history was related to treatment in the PS model [1.60 (1.56, 1.64) for Humana MA; 1.27 (1.20, 1.33) for Medicare FFS]. Only 82%-88% of the SU patients overall were matched. Balance was achieved with 1:1 matching in Humana MA for those without prior CVD where 90% of SU patients were matched (AMASD: overall PS: 0.01; subgroup-specific PS: 0.001), but imbalance was somewhat greater for patients with prior CVD where only 72% of SU patients were matched (overall PS: AMASD: 0.01, subgroupspecific PS: 0.01). PS distributions after matching were superimposable, however (not shown). For Medicare FFS, balance was achieved for those without prior CVD where 96% of SU initiators were matched (ASAMD using overall PS: 0.019; ASAMD using subgroup-specific PS: 0.01) and among patients with prior CVD where only 84% of the SU users were matched (ASAMD overall PS: 0.01; subgroup-specific PS: 0.01). Again, PS distributions were superimposable. In both subgroups, balance was only minimally better with the subgroup-specific PS compared with overall PS.
For stratified analyses, balance in the Humana MA cohort using subgroup-specific PS (AMASD: 0.03) was almost identical to using overall PS (0.03) for subgroup without prior CVD and for the subgroup with CVD history (subgroup-specific PS AMASD: 0.03 and overall PS AMASD: 0.02). For Medicare FFS stratified analyses, balance was comparable among those without prior CVD (ASAMD overall PS: 0.03; subgroup-specific PS: 0.04) and among those with prior CVD (0.03 and 0.03 for overall and subgroup-specific PS, respectively). ASAMD estimates were lower for matching than for stratification across subgroups and cohorts.
Crude HR estimates (± 95% CI) for nonfatal MI with SU versus MET were higher for the older cohorts [HR: 2.1 (1.9-2.3) for Humana MA and HR: 2.2 (1.9-2.5) for Medicare FFS] than for the younger cohort (Fig. 3) . HR estimates were consistent between overall and subgroup-specific PS for 1:1 matching within those without prior CVD (HR: 1.4-1.9) and those with prior CVD (HR: 1.5-1.7), differing by 3%-8% within the older cohorts. PS stratification showed similar patterns, differing by <1% within subgroups. Including race (not available in other datasets) in PS derivation for FFS did not change results.
DISCUSSION
On the basis of US cohorts of younger and elderly T2DM patients initiating MET or SU, an overall PS balanced nearly as well in matching within subgroups as a subgroupspecific PS in assessing the association between monotherapy and MI. After PS implementation, subgroup-specific PS showed slightly better balance within the subgroup with prior CVD, but the differences were small, and HRs for MI were highly consistent across cohorts, regardless of whether matching or stratification was applied or overall versus subgroup-specific PS was used. If the relationship between covariates and treatment varies by a strong confounder, a subgroup-specific PS could potentially provide better balance covariates in subgroupmatched analyses, especially when the influence of covariates on treatment selection is not comparable across subgroups. In our case, particularly in the younger cohort, baseline differences between groups were minimal, perhaps reflecting the new user (initiators of therapy), active comparator design applied and the assessment of monotherapy, resulting in predominantly newly diagnosed T2DM with minimal complications and comorbidities. Even in the elderly diabetes cohorts, differences between groups were not pronounced despite greater prevalence of comorbidities and complications. The lower prevalence of CVD in the younger cohort may help explain the somewhat greater imbalance observed with stratification methods, and the consistency in HRs for this cohort.
We hypothesized that CVD history could be a strong confounder given its strong predictive properties for nonfatal AMI and CVD outcomes in general, and the potential to influence prescribing of oral antihyperglycemic agents. 10 A few studies have suggested that MET may reduce cardiovascular risk, whereas other studies suggest that mortality may be increased with use of SU. [7] [8] [9] We assessed the strength of the association of CVD history with SU and MET initiation, and found it to be moderately but significantly associated. CVD history may be of greater importance in the Humana cohort, given the significant reduction in ASAMD when stratifying by CVD subgroup.
This study included patients treated with SU or MET monotherapy who were naive to diabetes pharmacological treatment. However, treatment complexity in diabetes is strongly related to duration of diabetes and microvascular complications, and also to cardiovascular outcomes. We expect that a greater degree of confounding would be more likely in patients with longer duration diabetes and with more complex treatment regimens. In addition, we expected significant channeling bias due to concerns about hypoglycemia when adding SU to existing diabetes regimens in patients with longer term diabetes, especially in the elderly. We did not assess more complex regimens of SU or MET initiators already on a background of other diabetes therapies as our objective was to study monotherapy and MET is overwhelmingly used first line.
Our results are in agreement with Rassen et al, 6 who showed that a correctly specified cohort PS can be applied in subgroup analyses, based on simulations and 2 empirical examples. This was supported by small differences (< 10%) in estimated log odds ratios in empirical analyses when the full cohort PS was applied to a subgroup analysis, similar to our findings. Differences were larger with small subgroups (n < 1000) or rare outcomes, which was confirmed in simulation analyses. However, the strength of confounding with the subgroups they assessed (sex, age, and risk) was unclear, whereas we report the association of CVD in the PS model. In addition, their simulations were based on outcome model adjustment for PS, not on applying 1:1 PS matching and stratification, as in our analyses. Neither of our studies included interactions in modeling PS, an area that deserves further research. However, because of the consistency of our findings between overall and subgroup-specific PS, adding interactions would be unlikely to change our results. Finally, our results address an important methodological question in the area of diabetes, and one highly relevant to the mini-Sentinel protocol.
Certain limitations should be considered in interpreting these results. Our analyses are based on a younger and 2 elderly cohorts with T2DM, in 3 separate claims databases, which could not be combined due to inherent differences in the populations. Generalizability is hence limited to the insured in the younger group, and in the elderly, to those who choose the Medicare Advantage or FFS plans. We did not have information on ethnicity except in Medicare FFS where it seemed to not influence results. Balance was assessed Propensity Score Derivation for Subgroup Analyses using the commonly used ASAMD that has the advantage of being an overall balance metric, but does not account for strength of association to outcome. However, we included the most important confounders in PSs which indirectly assures inclusion of covariates associated with outcome. The small reductions in ASAMD with the various techniques are difficult to interpret without standards, and could benefit from further research. Finally, information on fatal MI, other cardiovascular deaths, and other cardiovascular events were not available. Our primary goal was to assess differences when applying an overall versus a subgroup-specific PS, not to assess differences in AMI between SU versus MET per se. Results may be dependent on the disease, outcome, and confounder as well as the exposures studied. Further research is needed through other empirical examples and simulations in which the covariates may have different relationships with the potential subgroup variable.
The strengths of our analyses are that 3 separate claims databases and 2 age cohorts were analyzed, and several approaches to control for confounding were used. These cohorts and the available information on medical history, prior and concomitant therapies, and comorbidities, reflect the types of studies in which PS methods are typically applied to control for confounding in comparative effectiveness research.
CONCLUSIONS
In this study, balance of baseline covariates between treatment groups was achieved with both overall cohort and subgroup-specific PSs in analyses of the effect of SU versus MET monotherapy with nonfatal MI in patients with diabetes across 3 cohorts and within and across CVD subgroups, with only minimally better balance for subgroup-specific PSs. Matching achieved better balance than stratification on PS but with expected loss in sample size. Our study is limited insofar as crude differences were minimal, suggesting that the new user, active comparator design identified patients with some equipoise between treatments.
